Table 2.
(Bio)markers and the differences between patients receiving at least three courses of anthracyclin-containing chemotherapy and healthy controls
| Variable | Controls (n = 14) | Patients (n = 21) | Patients versus controls | 95%-Confidence interval | P value | |
|---|---|---|---|---|---|---|
| Lower | Upper | |||||
| ANP (pmol/L) | 11.3 | 20.7 | 82.9% | −0.2% | 235.0% | 0.05 |
| CK-MB mass (mg/L) | 1.1 | 0.9 | −15.7% | −48.1% | 37.0% | 0.48 |
| NT-proBNP (ng/L) | 39.5 | 148.9 | 276.6% | 86.3% | 661.4% | <0.001 |
| HR (bpm) | 67 | 71 | 4.20 | −1.95 | 10.36 | 0.17 |
| QT (ms) | 400 | 400 | −0.31 | −18.1 | 17.47 | 0.97 |
| QTc Bazett (ms) | 420 | 433 | 13.05 | −0.36 | 26.46 | 0.06 |
| QTc linear (ms) | 414 | 422 | 8.22 | −2.68 | 19.13 | 0.13 |
Average values of biochemical markers and ECG parameters and contrasts between anthracyclin-chemotherapy completers and controls, including 95%-confidence intervals and P values (for the biochemical markers contrasts are represented in percentage difference, for ECG parameters results are shown in absolute differences)
ANP atrial natriuretic peptide, CK-MB creatine kinase isoenzyme MB, NT-proBNP N-terminal pro brain natriuretic peptide, HR heartrate, QT QT-interval, QTc Bazett QT interval corrected according to Bazett, QTc linear QT interval corrected according to Framingham’s linear correction method
Averages are estimated, as MIXED model analysis was used to correct for predose and missing values